Dissociation of tumor promoter-stimulated ornithine decarboxylase activity and DNA synthesis in mouse epidermis in vivo and in vitro by fluocinolone acetonide, a tumor-promotion inhibitor. 1977

U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa

12-O-Tetradecanoyl phorbol-13-acetate (TPA), a tumor promoter, stimulates DNA synthesis in mouse epidermal cells in vivo and in vitro. This response appears to be mediated through polyamine metabolism because ornithine decarboxylase (L-ornithine carboxy-lyase, EC 4.1.1.17)activity is markedly increased shortly after promoter exposure and this induction varies in magnitude according to dose and promoter potency of a series of phorbol esters. In vitro, exogenous putrescine (0.01-10 mM) results in a dose-related increase and prolongation of promoter-stimulated DNA DNA synthesis, a phenomenon noted in other systems of polyamine-mediated growth stimulation. The anti-inflammatory steroid fluocinolone acetonide (FA), an inhibitor of tumor promotion, prevents TPA stimulation of epidermal proliferation in vivo and in vitro. In vitro, FA most effectively prevents stimulation of DNA synthesis when applied is not required. Paradoxially, FA potentiates the increase in ornithine decarboxylase activity after TPA administeration both in vivo and in vitro. Furthermore, the inhibition of TPA-stimulated DNA synthesis by FA in vitro can be reversed by exogenous putrescine. These results suggestthat FA exerts its antipromotion effect by reducing the sensitivity of the cell to polyamines or by reducing intracellular polyamine levels.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009955 Ornithine Decarboxylase A pyridoxal-phosphate protein, believed to be the rate-limiting compound in the biosynthesis of polyamines. It catalyzes the decarboxylation of ornithine to form putrescine, which is then linked to a propylamine moiety of decarboxylated S-adenosylmethionine to form spermidine. Ornithine Carboxy-lyase,Carboxy-lyase, Ornithine,Decarboxylase, Ornithine,Ornithine Carboxy lyase
D011700 Putrescine A toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine. 1,4-Butanediamine,1,4-Diaminobutane,Tetramethylenediamine,1,4 Butanediamine,1,4 Diaminobutane
D002262 Carboxy-Lyases Enzymes that catalyze the addition of a carboxyl group to a compound (carboxylases) or the removal of a carboxyl group from a compound (decarboxylases). EC 4.1.1. Carboxy-Lyase,Decarboxylase,Decarboxylases,Carboxy Lyase,Carboxy Lyases
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D004261 DNA Replication The process by which a DNA molecule is duplicated. Autonomous Replication,Replication, Autonomous,Autonomous Replications,DNA Replications,Replication, DNA,Replications, Autonomous,Replications, DNA
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005260 Female Females
D005446 Fluocinolone Acetonide A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732) Fluortriamcinolone Acetonide,Alvadermo,Capex,Co-Fluocin,Cortiespec,Derma-Smooth FS,Flucinar,Fluocid,Fluodermo,Fluonid,Fluotrex,Flurosyn,Flusolgen,Gelidina,Jellin,Jellisoft,Synalar,Synalar-HP,Synamol,Synemol,Acetonide, Fluocinolone,Acetonide, Fluortriamcinolone,Co Fluocin,Derma Smooth FS,Synalar HP

Related Publications

U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa
June 1977, Chemico-biological interactions,
U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa
October 1979, Cancer research,
U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa
December 1977, Biochemical and biophysical research communications,
U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa
June 1991, Cancer research,
U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa
November 1983, Cancer research,
U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa
March 1978, Cancer research,
U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa
October 1975, Biochimica et biophysica acta,
U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa
February 1979, Cancer research,
U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa
June 1990, Cancer letters,
U Lichti, and T J Slaga, and T Ben, and E Patterson, and H Hennings, and S H Yuspa
October 1990, Carcinogenesis,
Copied contents to your clipboard!